Dyschromatosis universalis hereditaria is a rare genodermatosis characterized by reticulate hyper- and hypo- pigmentated macules in a generalized distribution. : 856 Both autosomal dominant and recessive inheritance have been reported with the disorder.It has been associated with mutations in genes SASH1 and ABCB6. References
External links

Dyschromatosis universalis hereditaria: Two cases, Dermatology Online Journal.
The applicant for this medicinal product is Deciphera Pharmaceuticals (Netherlands) B.V. Ripretinib was approved for medical use in the European Union in November 2021. Names
Ripretinib is the International nonproprietary name (INN) and the United States Adopted Name (USAN). References
Further reading
Schneeweiss M, Peter B, Bibi S,  et al. (May 2018). "The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis". Haematologica. 103 (5): 799–809. doi:10.3324/haematol.2017.179895. PMC 5927976. PMID 29439183. External links
"Ripretinib". Drug Information Portal. U.S. National Library of Medicine. "Ripretinib". NCI Drug Dictionary. National Cancer Institute. "Ripretinib". National Cancer Institute. 27 May 2020. Clinical trial number NCT03353753 for "Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)" at ClinicalTrials.gov